Meeting
2015 Gastrointestinal Cancers Symposium
A multi-institutional feasibility study of S-1/oxaliplatin (SOX) plus bevacizumab in patients with advanced/metastatic colorectal cancer: HiSCO-02 prospective phase II study.
Authors
Manabu Kurayoshi
Higashihiroshima Medical Center, Higashihiroshima, Japan
Manabu Kurayoshi , Katsunori Shinozaki , Takao Hinoi , Tsuyoshi Kobayashi , Manabu Shimomura , Masanori Yoshimitsu , Kazuhiro Toyota , Masahiro Nakahara , Yasuyo Ishizaki , Yuzo Hirata , Shinya Kodama , Yosuke Shimizu , Koji Kawaguchi , Masakazu Tokunaga , Daisuke Sumitani , Hideki Ohdan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
UMIN000004976
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 728)
DOI
10.1200/jco.2015.33.3_suppl.728
Abstract #
728
Poster Bd #
E18
Abstract Disclosures
Similar Posters
Poster
2014 Gastrointestinal Cancers Symposium
Final results of phase II study of S-1, oral leucovorin, oxaliplatin, and bevacizumab combination therapy (SOL+BV; SOLA) in metastatic colorectal cancer (mCRC).
First Author: Kentaro Yamazaki
Poster
2014 Gastrointestinal Cancers Symposium
Efficacy and safety of FOLFOX biweekly cetuximab as first-line therapy for patients with nonresectable metastatic colorectal cancer (CELINE trial): Multicenter phase II trial.
First Author: Ken Kondo
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando
Poster
2022 ASCO Annual Meeting
Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.
First Author: Zhichao Jiang